Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Common Stock Issued

Cash raised by issuing new shares.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued turns negative

Q1 FY2026 common stock issued was -$263K, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $24.78M. Over 3 fiscal years it compounded at +213.2% a year.

Context

  • Common stock issued amounted to 206.3% of revenue in FY2025, up 201.6 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly common stock issued holds near -$263K or moves back toward the trailing-twelve-month quarterly average of $6.19M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$263K-101.1% QoQ
Last fiscal yearDec 2025
$25.04M+7511.2% YoY
LTMMar 2026
$24.78M+7477.4% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+7511.2%——
3-year CAGR+213.2%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
25.04M USD
Year-over-year change
+7511.2%
4-year CAGR
-37.2%

Common Stock Issued vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7477.4% is the 2nd highest of 11, against a peer median of +177.0%.
  • Common stock issued amounts to 148.2% of revenue for PRLD, versus a peer median of 209.0%.
PRLD Competitors
Common Stock Issued for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€237.74M EUR+314.6%+199.8%5303.2%
IMRXImmuneering CorporationLTM Mar 2026$212.95M USD+1117.0%+2184.5%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.32M USD+280.7%+93.7%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$77.76M USD+406.7%-13.1%237.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$70.1M USD+36792.1%-81.0%101.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$58.15M USD+13.5%+11.9%25842.7%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.88M USD-51.5%-16.6%180.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$24.78M USD+7477.4%+213.2%148.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$17.28M USD-90.7%+420.6%29279.7%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$7.51M USD+73.4%+31.2%67.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$740K USD-53.3%—5.3%
Peer median (excluding PRLD) —+177.0%+31.2%209.0%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.